Survey of the year 2007 commercial optical biosensor literature

Abstract

In 2007, 1179 papers were published that involved the application of optical biosensors. Reported developments in instrument hardware, assay design, and immobilization chemistry continue to improve the technology's throughput, sensitivity, and utility. Compared to recent years, the widest range of platforms, both traditional format and array-based, were used. However, as in the past, we found a disappointingly low percentage of well-executed experiments and thoughtful data interpretation. We are alarmed by the high frequency of suboptimal data and over-interpreted results in the literature. Fortunately, learning to visually recognize good--and more importantly, bad--data is easy. Using examples from the literature, we outline several features of biosensor responses that indicate experimental artifacts versus actual binding events. Our goal is to have everyone, from benchtop scientists to project managers and manuscript reviewers, become astute judges of biosensor results using nothing more than their eyes.

The Molecular Pharmacology and In Vivo Activity of 2-(4-Chloro-6-(2,3-dimethylphenylamino)pyrimidin-2-ylthio)octanoic acid (YS121), a Dual Inhibitor of Microsomal Prostaglandin E2 Synthase-1 and 5-Lipoxygenase

“…Direct interference of YS121 with mPGES-1 is demonstrated in two ways: 1) by suppression of mPGES-1-mediated transformation of PGH 2 to PGE 2 in the cell-free assay and 2) by physical interaction of YS121 with mPGES-1 using SPR spectroscopy, yielding concrete data on rate constants of the association and dissociation phase, the equilibrium constants, and the stoichiometry. Reliable controls are obligatory for binding studies to exclude unspecific interactions between analyte, immobilized macromolecule, or surrounding matrix (Rich and Myszka, 2008). In fact, at concentrations Ͼ10 M, YS121 also binds to the reference dextran surface and causes aggregation or micelle formation with superstoichiometric binding pattern (Giannetti et al, 2008).…”

Complementary Use of Label-Free Real-Time Biosensors in Drug Discovery of Monoclonal Antibodies

“…These collaborations enhance the biosensor community's ability to design experiments and provide insights into the variability of biosensor data where it can become difficult to www.intechopen.com discriminate between sub-optimal instrument quality and an unskilled user. Inspired by these studies and the continuing evolution of biosensors, we compared the performances of two parallel-processing platforms, namely the Octet QK and the ProteOn XPR36 interaction array, head-to-head with the serial flow Biacore 3000 unit that represents the current "workhorse" of the biosensor research commun i t y a s j u d g e d f r o m i t b e i n g t h e m o s t frequently cited platform in the literature (Rich & Myszka, 2008). First, we addressed binding kinetics which is perceived as the signature role of biosensors based upon the abundance of literature on the topic.…”

Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays

“…The binding of an analyte to a surface receptor immobilized on the metal surface perturbs the resonance conditions resulting in a shifted resonance dip, which can then be correlated to the analyte concentration. SPR-based biosensors are now commercially available that offer a real-time, label free technique to monitor biomolecular binding events and biochemical reactions [8][9][10] . The image is then captured onto a charge-coupled device (CCD) array.…”